Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)

Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

B.-J. Sung, Kwang Yeon Hwang, Young Ho Jeon et al. · Nature · 2003 · 278 citations

Life Sciences, Biochemistry, Medicinal Chemistry +16

Phosphorylation of phosphodiesterase‐5 by cyclic nucleotide‐dependent protein kinase alters its catalytic and allosteric cGMP‐binding activities

Jackie D. Corbin, Illarion V. Turko, Alfreda Beasley et al. · European Journal of Biochemistry · 2000 · 268 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Pharmacology of phosphodiesterase inhibitors

2005 · 263 citations

Medicine, Pharmacokinetics, Pharmacology +13

PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS

Corbin Jd, Francis Sh · International Journal of Clinical Practice · 2002 · 258 citations

Medicine, Pharmacokinetics, Pharmacology +13

Effects of sildenafil, a type‐5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum <i>in vitro</i>

Jamie Y. Jeremy, Stephen A. Ballard, A.M. Naylor et al. · British Journal of Urology · 1997 · 250 citations

Medicine, Pharmacology, Pharmacotherapy +14